May 2 (Reuters) - Acrux Ltd (ACR)
- U.S. Patent and Trademark Office has instituted an inter partes review (IPR) proceeding filed by Acrux against U.S. Patent no. 7,214,506
- Patent relates to methods of using various antifungal compounds, including efinaconazole, for treatment of onychomycosis
- U.S. Patent No. 7,214,506 is owned by Kaken Pharmaceutical Co Ltd. and licensed to Valeant Pharmaceuticals International Inc
Add to My Watchlist
What is My Watchlist?